Roberto Rodríguez-Labrada

TL;DR: TMS markers of CST dysfunction progress significantly during the pre-ataxic stage of SCA2, and may provide biomarkers of disease progression prior to clinical disease expression that have potential utility for monitoring neuroprotective therapies in future clinical trials.

TL;DR: This study demonstrates for the first time in SCAs that CMCT measures by TMS has superior sensitivity when compared with a standard neurological examination to detect involvement of the corticospinal tract in the prodromal phase of SCA2.

TL;DR: In this article, the authors identify a set of gait measures from body-worn inertial sensors that best discriminate between people with prodromal or manifest spinocerebellar ataxia (SCA) and age-matched, healthy control subjects (HC) and determine how these measures relate to disease severity.

TL;DR: The wide epidemiological, clinical, and genetic characterization of this founder SCA2 population identifies this homogeneous cohort as an attractive source for the development of future clinical-genetic and therapeutic researches.

TL;DR: Speech and swallowing deficits appear sensitive to disease progression in early-stage SCA2, with syllabic rate a viable marker.